Adalvo proudly announces the addition of Lenvatinib 4mg/ml Oral Solution to our product portfolio.
Our product, developed based on the reference brand LENVIMA, serves as a vital treatment for Differentiated Thyroid Carcinoma (DTC), Hepatocellular Carcinoma (HCC), and Endometrial Carcinoma (EC).
In 2023, the brand achieved global sales of approximately $1.76 billion, with a Global 3-year Compound Annual Growth Rate (CAGR) of 16%, as reported by IQVIA.
As a value-added product, Lenvatinib 4mg/ml Oral Solution addresses critical unmet medical needs in the oncology sector. With a clearly defined product pathway, we anticipate a Day-1 launch across all major markets, underscoring our commitment to prompt accessibility and patient care.
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
Click Here To Get In Touch!